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There are few biomarkers to predict efficacy of glucocorticoid treatment in childhood acute 
lymphoblastic leukemia (ALL) at diagnosis. Here, we demonstrate reciprocal regulation of 
11β-HSD, may predict the apoptotic response of ALL to glucocorticoid treatment. Our data 
may be useful to refine glucocorticoid treatment, to retain benefit whilst minimizing side-
effects. 
 
The synthetic glucocorticoids, dexamethasone and/or prednis(ol)one, form crucial first-line 
treatment for childhood acute lymphoblastic leukemia (ALL). The response to initial 
glucocorticoid treatment is a strong prognostic indicator of treatment outcome.
1
 ALL cells 
show differing degrees of glucocorticoid sensitivity/resistance at diagnosis and glucocorticoid 
resistance remains a therapeutic problem.
2
 Identification of biomarkers of glucocorticoid 
sensitivity/resistance would be useful in order to stratify therapy. This would facilitate 
targeting of high dose glucocorticoid therapy to those children with resistant disease, most 
likely to benefit. Low glucocorticoid receptor (GR) levels may be a common though hard to 
detect mechanism of glucocorticoid resistance.
3
 Downstream markers of glucocorticoid 
action may be more sensitive indicators of glucocorticoid responsiveness. The glucocorticoid 
metabolizing enzymes, 11β-hydroxysteroid dehydrogenase types 1 and 2 (11β-HSD1 and 
11β-HSD2, respectively) are regulated by glucocorticoids in a number of cell types, including 
ALL cells,
4,5,6
 and may therefore act as biomarkers of glucocorticoid responsiveness. 11β-
HSD1 predominantly regenerates active glucocorticoids (cortisol, corticosterone) from inert 
11-keto forms (cortisone, 11-dehydrocorticosterone), whereas 11β-HSD2 catalyses the 
reverse reaction.
4
 In a pilot study, we demonstrated induction of HSD11B1 (encoding 11β-
HSD1) by dexamethasone in glucocorticoid-sensitive childhood ALL, but repression in 
glucocorticoid-resistant samples.
7
 There are few data on dexamethasone regulation of 
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HSD11B2 (encoding 11β-HSD2) in childhood ALL, but one report suggests down-regulation 
in glucocorticoid-sensitive ALL.
8
 Moreover, expression of 11β-HSD2 contributes to 
prednisolone resistance in lymphoblastic leukemia cells.
9,10
 Recently, we have shown 
reciprocal regulation of 11β-HSD1/2 may predict steroid sensitivity in childhood nephrotic 
syndrome.
11
 Therefore we hypothesized that expression of both 11β-HSD1 and -2 is 
glucocorticoid-regulated and associated with glucocorticoid sensitivity in childhood ALL. 
Methods 
Patients ALL patients were recruited from the Royal Hospital for Sick Children (Edinburgh) 
and the Royal Hospital for Sick Children (Glasgow), UK, between November 2011-
November 2015. The study was approved by the National Cancer Research Network 
Coordinating Centre (MREC, 10/S0709/35). Additional patients were recruited from 
Hamamatsu University School of Medicine, Japan between November 2011-December 2015 
(project approval number, 16-38).  Study protocols were approved by the ethics committees 
of the respective hospitals. Peripheral blood and/or bone marrow samples were obtained at 
diagnosis of ALL with informed consent. Diagnosis of ALL was made by pediatric 
hematologists based on clinical and laboratory findings. Leukemic cells were isolated by 
density gradient centrifugation (Ficoll-Paque PLUS; GE Healthcare Life Sciences, Little 
Chalfont, Bucks, UK) and duplicate or triplicate samples cultured for 24h in the presence or 
absence of dexamethasone (10
-6
M). Minimal residual disease (MRD) at day 29 of remission 
induction was measured for UK samples by flow cytometry, as part of the UKALL2011 trial.  
Cell culture CCRF-CEM (JCRB9023) and MOLT4F (JCRB0021) T-lymphoblastic leukemia 
cells were obtained from the Health Science Research Resources Bank (Osaka, Japan). 
1.0×10
6
 cells/well were seeded in triplicate in 12-well plates in RPMI-1640 supplemented 
with 10% fetal calf serum, penicillin (100U/mL) and streptomycin (100μg/mL) 













M) or methotrexate (10
-6
M) (all 
Sigma-Aldrich, Gillingham, Dorset, UK).  Vincristine and Methotrexate treatments were  24h. 
RNA extraction and real-time qPCR RNA was extracted using Trizol (ThermoFisher 
Scientific). RNA (1µg) was reverse transcribed using SuperScript III (ThermoFisher 
Scientific) and quantified by qPCR (in triplicate) using a LightCycler (Roche, Burgess Hill, 
Sussex, UK) as previously described.
7,9
 Mastermix and primer-probe sets for HSD11B1, 
HSD11B2, NR3C1 and 18S RNA (internal control) were from ThermoFisher Scientific. 
Cell viability assay For cell lines, flow cytometry was used to measure apoptosis following 
annexin-V and propidium iodide staining (Annexin-V Apoptosis Detection Kit FITC, 
ThermoFisher Scientific). Fluorescence was measured by FACScalibur using Cellquest 
(Becton Dickinson Ltd, Oxford, UK) with 10,000 cells/sample acquired; data were analyzed 
using FlowJo software (Treestar, Ashland, Oregon, USA). For patient samples, 1×10
5
 
cells/well were seeded in 96-well plates and cell viability measured by MTT assay (Sigma-





M) for 96h. Samples were classified as glucocorticoid-sensitive or 
resistant, as previously described.
7,12
 
Statistics Data from cells and patient samples were analyzed using ANOVA and Paired t-test 
(2-tailed) with significance set at P<0.05. Values are mean±SEM. Patient characteristics and 
gene profiles were compared using Mann-Whitney U test for age and the chi-squared test for 
gender, immuno-phenotype, MRD and gene expression (JMP software). 
Results 
We first measured levels of HSD11B1 and HSD11B2 mRNA (encoding 11β-HSD1 and 11β-
HSD2, respectively) in glucocorticoid-sensitive CCRF-CEM lymphoblastic leukemia cells.
9
 
As expected, cellular apoptosis was increased following 24h incubation with dexamethasone, 
in a dose-dependent manner (Figure 1a). HSD11B1 mRNA levels were increased and 
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HSD11B2 mRNA levels decreased by dexamethasone, in a dose dependent manner (Figure 
1b) that paralleled cellular apoptosis. Consistent with previous reports,
13
 levels of NR3C1 
mRNA encoding GR were increased by dexamethasone (Figure 1b). In contrast to NR3C1 
mRNA, which was already increased 2h after dexamethasone addition (Figure 1d), the 
increase in cellular apoptosis was apparent only 24h after addition of dexamethasone (Figure 
1c). Similarly, HSD11B1 mRNA levels only increased 24h following addition of 
dexamethasone, suggesting this is a late glucocorticoid response. HSD11B2 mRNA levels 
were significantly reduced 24h after dexamethasone addition (Figure 1d). These data suggest 
that induction of HSD11B1 and repression of HSD11B2 are associated with cellular apoptosis.  
Next, we investigated the regulation of HSD11B1 and HSD11B2 in glucocorticoid resistant 
MOLT4F cells in which high expression of 11β-HSD2 contributes to prednisolone 
resistance.
9
 Dexamethasone had no significant effect upon apoptosis in MOLT4F cells 
(Figure 1e). In contrast to glucocorticoid sensitive CCRF-CEM cells, neither HSD11B1 nor 
HSD11B2 mRNA levels were affected by dexamethasone in MOLT4F cells (Figure 1f), 
possibly secondary to the very low levels of NR3C1 expression in these cells.
9
 Interestingly, 
the anti-leukemic drugs vincristine and methotrexate, both of which induced apoptosis in 
MOLT4F cells (Figure 1e), increased HSD11B1 and decreased HSD11B2 mRNA levels 
without affecting NR3C1 mRNA levels (Figure 1f). Thus, as in CCRF-CEM cells, induction 
of HSD11B1 and repression of HSD11B2 is associated with induction of apoptosis. These 
data suggest that HSD11B1 and HSD11B2 may be sensitive biomarkers to predict the 
apoptotic response of ALL cells to chemotherapy more generally, although this requires 
testing with vincristine and methotrexate in patient samples. Whether and how manipulation 
of these genes affect cell apoptosis remains to be determined. 
Findings in cell lines do not necessarily translate to patient samples. To test whether 
HSD11B1 and HSD11B2 are differentially regulated in glucocorticoid sensitive and resistant 
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childhood ALL, we measured HSD11B1 and HSD11B2 mRNA levels in cells from patients, 
obtained at diagnosis, prior to initiation of treatment. Where sufficient cells were available, 
we assessed glucocorticoid sensitivity/resistance in vitro by methyl-thiazol-tetrazolium 
(MTT) assay with patients classified as GC-sensitive or resistant as previously described.
7,12
 
In a representative glucocorticoid-sensitive patient sample where both prednisolone and 
dexamethasone were effective inducers of cell death, dexamethasone treatment up-regulated 
HSD11B1 and down-regulated HSD11B2 mRNA levels (Figure 1g). In contrast, 
dexamethasone down-regulated HSD11B1 and up-regulated HSD11B2 mRNA levels in a 
representative glucocorticoid-resistant ALL patient sample (Figure 1h). NR3C1 mRNA levels 
were unchanged following dexamethasone in both GC-sensitive and resistant ALL patient 
samples (Figure 1g, 1h). Across all GC-sensitive patients, irrespective of B-ALL or T-ALL 
subtype, HSD11B1 was up-regulated in the majority (Table 1), whereas HSD11B2 was down-
regulated (Table 1). In contrast, in the majority of GC-resistant patients, HSD11B1 was 
down-regulated and HSD11B2 was up-regulated (Table 1). A chi-square test showed these 
differences between GC-sensitive and GC-resistant samples are significant.  
Discussion 
These data suggest that increased HSD11B1 and/or decreased HSD11B2 expression are 
associated with glucocorticoid-induced apoptosis whereas the opposite pattern, of decreased 
HSD11B1 and/or increased HSD11B2 expression is associated with resistance to 
glucocorticoid-induced apoptosis at diagnosis. The difference in NR3C1 regulation between 
GC-resistant and GC-sensitive ALL was not significant (Table 1), consistent with previous 
reports that GR up-regulation is not linked to GC-resistance in childhood ALL.
3
 Minimal 
residual disease (MRD), the most useful predictor to stratify patients,
14
 tended to be 
associated with GC-sensitivity/resistance, but did not achieve significance (Table 1). Whether 
the reciprocal regulation of HSD11B1 and HSD11B2 is a cause or a result of GC 
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sensitivity/resistance remains unknown. Dexamethasone, a poor substrate for 11β-HSD, was 
used here, suggesting the association reflects a cell state, rather than being causative. A 
previous report has suggested that 11β-HSD1 and 2 influence cell proliferation with 11β-
HSD1 reducing but 11β-HSD2 increasing cellular proliferation.
15
 Expression of 11β-HSD1 
and 11β-HSD2 is normally reciprocally regulated.
4
 Many cells/tissues switch from 11β-
HSD2 to 11β-HSD1 expression as they differentiate and mature. It is possible that the 
expression of 11β-HSD1 and 2 reflects the developmental state of ALL cells and produces 
opposing patterns of cell proliferation/apoptosis against GC treatment. Our findings are 
preliminary, qualitative rather than quantitative, and require confirmation in a larger number 
of patients. Nevertheless, 11β-HSD1/2 patterns may be useful biomarkers to predict which 
patients will respond well to glucocorticoids. This might enable glucocorticoid treatment to 
be tailored more to the individual child to maximize treatment benefit and minimize side-
effects.  
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Figure legend 
Figure 1. Reciprocal regulation of HSD11B1 and HSD11B2 is associated with apoptosis in 
lymphoblastic leukemia cells.  
Glucocorticoid-sensitive CCRF-CEM cells were treated with dexamethasone (DEX, black 
bars) ranging from 0-10
-6
M. (a) Apoptosis was measured by flow cytometry following 
staining with Annexin-V and propidium iodide. (b) Quantitative (q)PCR measurements of 
HSD11B1 (left), HSD11B2 (centre) and NR3C1 (right) mRNA. In a time course of the effects 
of 10
-6
M dexamethasone upon CCRF-CEM cells, cells were collected between 0-24h for 
10 
 
measurement of (c) apoptosis and (d) qPCR measurement of HSD11B1, HSD11B2 and 
NR3C1 mRNA. (e, f) 10
-6
M Dexamethasone (24h) had no effect on HSD11B1 and 2 mRNA 
expression, but 10
-6
M vincristine (VCR) and 10
-6
M methotrexate (MTX) 24h treatment 
increased HSD11B1 and decreased HSD11B2 mRNA levels in accordance with cell apoptosis 
in GC-resistant MOLT4F cells. Data are mean±SEM of at least three independent mRNA 
samples. RNA concentrations are expressed as fold-induction relative to vehicle treated cells 
(CON, white bars). (g, h) Left panels: qPCR measurements of HSD11B1, HSD11B2 and 
NR3C1 mRNA in representative patient samples. Data are the mean±SEM of duplicate (g) or 
triplicate (h) mRNA samples. Right panels: Viability of ALL cells following prednisolone 
(PRED) and dexamethasone (DEX) treatment in MTT assay. Significant effect of treatment, 
*p<0.05, **p<0.01. 
Table legend 
Table 1. Summary of ALL patient characteristics 
Patient characteristics were compared between groups using Mann-Whitney U test for age 
and the chi-squared test for gender, immuno-phenotype, gene expression and MRD. 
HSD11B1, HSD11B2 and NR3C1 had missing values due to insufficient sample. MRD data 
were only available for UK samples. Up-regulation was defined as more than 1.00-fold 
difference between vehicle and dex samples. Down-regulation was defined as less than 1.00-
fold difference between vehicle and dex samples. 
Table 1. Summary of ALL patient characteristics
n =37 GC-sensitive (n = 22 ) GC-resistant (n= 15 ) P (sensitive vs resistant)
Age (years), median (range) 5.91 (1-14) 6.0 (2-12)
Gender Boys 55% (12/22) 53% (8/15)
Girls 45% (10/22) 47% (7/15)
Immuno-phenotype B 73% (16/22) 80% (12/15)
T 27% (6/22) 20% (3/15)
HSD11B1 up-regulated 65% (13/20) 23% (3/13)
down-regulated 35% (7/20) 77% (10/13)
HSD11B2 up-regulated 24% (4/17) 70% (7/10)
down-regulated 76% (13/17) 30% (3/10)
NR3C1 up-regulated 53% (8/15) 73% (8/11)
down-regulated 47% (7/15) 27% (3/11)
MRD Low risk 67% (8/12) 29% (2/7)
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